Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» baricitinib
baricitinib
Lilly Rheumatoid Arthritis Drug Meets Goals in Final-Stage Trial
Bloomberg
Tue, 12/9/14 - 08:08 am
Eli Lilly
rheumatoid arthritis
baricitinib
Lilly says arthritis pill effective in mid-stage study
Reuters
Thu, 06/13/13 - 10:45 am
Eli Lilly
Incyte
baricitinib
rheumatoid arthritis
Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis
Yahoo
Thu, 11/15/12 - 11:06 am
baricitinib
Incyte
JAK inhibitors
Eli Lilly
rheumatoid arthritis
Lilly arthritis drug shows durability in study
Reuters
Tue, 11/13/12 - 05:36 pm
Eli Lilly
baricitinib
Incyte
rheumatoid arthritis
Eli Lilly: New Drug Shows Strong Potential
Seeking Alpha
Fri, 06/22/12 - 09:28 am
Eli Lilly
Incyte
baricitinib
Merck
Abbott Laboratories
AstraZeneca
Bristol-Myers Squibb
rheumatoid arthritis
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor
PharmPro
Sat, 06/9/12 - 04:54 pm
Eli Lilly
Incyte
LY3009104
baricitinib
rheumatoid arthritis
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Yahoo
Fri, 06/8/12 - 01:28 pm
Incyte
JAK inhibitors
baricitinib
Eli Lilly
rheumatoid arthritis
Pages
« first
‹ previous
1
2
3